Clinical Trials on Endometrioid Carcinoma in Netherlands

Total 937 results

European Organisation for Research and Treatment...

Completed

Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

France, Spain, Netherlands, Australia, United Kingdom, Italy, Portugal, Austria
AbbVie

Active, not recruiting

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Australia, Belgium, Bulgaria, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Puerto Rico, Romania, Russian Federation, Spain, Switzerland and more
Universitaire Ziekenhuizen KU Leuven
Eli Lilly and Company; European Network of Gynaecological Oncological Trial... and other collaborators

Recruiting

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer (ALEPRO)

Low Grade Serous Ovarian Carcinoma | Adult Type Granulosa Cell Tumor

Belgium, Netherlands, France
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Active, not recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian Neoplasms | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

United States, Netherlands, Spain, Finland, Italy, Poland, Belgium, Canada, France, Germany, Romania, Ukraine, Norway, United Kingdom, Israel, Greece, Denmark, Belarus, Czechia
AstraZeneca

Completed

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Ovarian Cancer

Canada, Czechia, Poland, Romania, United States, Belgium, France, Russian Federation, United Kingdom, Israel, Spain, Germany, Austria, Netherlands, Australia, Estonia, Ukraine
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
Daiichi Sankyo, Inc.
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary...

Terminated

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Non Squamous, Non-small-cell Lung Cancer

Poland, France, Germany, Italy, Spain, Canada, United States, Argentina, Belgium, Mexico, Australia, Russian Federation, Netherlands, Peru, Brazil, Austria, United Kingdom, Sweden, Czechia, Chile, Denmark, Hungary, Romania
GlaxoSmithKline

Terminated

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

United States, Australia, Canada, Netherlands, Finland, Taiwan, Czechia, Estonia, Spain, Argentina, Belgium, France, Sweden, Germany, Israel, Italy, Korea, Republic of, Singapore, Ukraine, United Kingdom, Austria, Ireland, Thailand, C... and more
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

Squamous Non-Small Cell Lung Cancer

United States, Spain, France, Australia, Germany, Taiwan, Canada, Argentina, Belgium, Singapore, Brazil, Netherlands, Israel, Portugal, Russian Federation, Japan, Italy, Chile, Latvia, Peru, Ukraine, Lithuania, Slovakia, Bulgaria, Mexico, Austri...
Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, China, Korea, Republic of, Belgium, Hong Kong, Japan, Taiwan, Denmark, Germany, Israel, Poland, Italy, United Kingdom, Bulgaria, Czechia, Portugal, Switzerland, Greece, Turkey, Romania, Sweden, France, Singapore, Mexico, ... and more
AstraZeneca
Parexel

Active, not recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, Romania, Canada, Korea, Republic of, Brazil, Hungary, Japan, China, Taiwan, Hong Kong, United Kingdom, Germany, Poland, Australia, Netherlands, Serbia, India, Argentina, Ireland
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)

Advanced Cholangiocarcinoma | FGFR2 Gene Rearrangements

United States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
Pfizer

Completed

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)

Non Squamous Lung Cancer

United States, Switzerland, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Japan, Germany, Luxembourg, Australia, France, Brazil, Italy, Hong Kong, China, Belgium, Russian Federation, Austria, Finland, Portugal and more
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START) (START)

Non-small Cell Lung Cancer

United States, Sweden, Australia, Czech Republic, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Germany, China, Poland, Romania, Denmark, Hong Kong, Canada, Austria, Belgium, Hungary, Israel, Nether... and more
Amgen

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC)

United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, China, Czechia, Italy, Portugal, Thailand, Hong Kong, Singapore, Bulgaria, Turkey, Mexico, Argentina and more
AbbVie

Completed

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Squamous Non-Small Cell Lung Cancer

United States, Australia, Austria, Belarus, Brazil, Canada, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Norway, Poland, P... and more
Hoffmann-La Roche

Completed

A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy

Non-Squamous Non-Small Cell Lung Cancer

China, Korea, Republic of, South Africa, Taiwan, Hungary, France, Netherlands, United States, Bulgaria, Slovakia, Canada, Italy, Brazil, Thailand, Romania, Lithuania, Poland, Latvia, Ukraine, Czech Republic
Eli Lilly and Company

No longer available

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Metastatic Gastric Cancer | Metastatic Adenocarcinoma of the Gastroesophageal Junction

Germany, Netherlands, Austria, Greece, Korea, Republic of
Relay Therapeutics, Inc.

Active, not recruiting

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, Adult

United States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma

United States, Canada, Belgium, France, Germany, Italy, China, Spain, Japan, United Kingdom, Netherlands, Switzerland, Austria, Denmark, Finland, Ireland, Israel, Norway, Sweden
Hoffmann-La Roche

Completed

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Non-Squamous Non-Small Cell Lung Cancer

United States, France, Austria, Denmark, Italy, Spain, Germany, Mexico, Netherlands, Japan, Brazil, Greece, Argentina, Slovakia, Lebanon, Belgium, Oman, United Arab Emirates
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

Non-Small Cell Lung Cancer

United States, Italy, Poland, Spain, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Japan, Korea, Republic of, Lebanon, Mexico, Netherlands and more
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)

Carcinoma, Non-Small-Cell Lung | Neoplasm Metastasis

United States, China, Taiwan, Belgium, Australia, Japan, United Kingdom, Spain, France, Germany, Austria, Korea, Republic of, Hungary, Switzerland, Mexico, Norway, Italy, Turkey, Greece, Portugal, Netherlands, India, Romania, Canada, De... and more
AbbVie

Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Argentina, Brazil, Bulgaria, Chile, Czechia, Greece, Italy, Japan, Korea, Republic of, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, Australia, France, Belgium, China, Austria, United Kingdom, Germany, South Africa, Mexi... and more
Astellas Pharma Inc
Seagen Inc.

Completed

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)

Urologic Neoplasms | Urinary Bladder Neoplasms | Carcinoma, Transitional Cell | Ureteral Neoplasms | Urothelial Cancer | Urethral Neoplasms | Renal Pelvis Neoplasms

United States, Korea, Republic of, Spain, France, Germany, Italy, Japan, Netherlands
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
Pfizer

Terminated

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Ovarian Cancer

United States, Canada, United Kingdom, Korea, Republic of, Netherlands, Hong Kong, Singapore, Ireland, Estonia, Japan, Taiwan, Italy, Turkey, Slovakia, Germany, Poland, Switzerland, Croatia, Hungary, Bulgaria, Latvia, Mexico, Romania, Russian Federation and more
Sanofi

Active, not recruiting

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients (CARMEN-LC03)

Non-small Cell Lung Cancer Metastatic

Greece, Italy, Hungary, Belgium, Korea, Republic of, Turkey, Argentina, China, Spain, Chile, Poland, Australia, United States, Russian Federation, Brazil, Bulgaria, Canada, France, Germany, India, Israel, Japan, Lithuania, Mexico, Nethe... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-line NSCLC (JAVELIN Lung 100)

First Line Non-Small Cell Lung Cancer

Spain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

Non-small Cell Lung Cancer

United States, Korea, Republic of, China, Japan, Taiwan, Brazil, Argentina, Chile, Netherlands, Hong Kong, Spain, Italy, France, United Kingdom, Canada, Germany, Israel, Mexico, Portugal, Turkey, Austria, Belgium, Singapore
Hoffmann-La Roche

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Endocrine System Diseases | Gastrointestinal Neoplasms | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Respiratory Tract... and other conditions

France, Spain, United States, Korea, Republic of, United Kingdom, Taiwan, China, Belgium, Singapore, Netherlands, Germany, Italy, Hong Kong
AbbVie

Completed

Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE)

Small Cell Lung Cancer

United States, Australia, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Korea, Republic of, Latvia, Mexico, Netherlands, Poland, Portugal, Romania, Russian... and more
Hoffmann-La Roche

Completed

A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Non-Squamous Non-Small Cell Lung Cancer

Australia, France, Germany, Spain, China, Hong Kong, Canada, Sweden, Colombia, Taiwan, United Kingdom, Russian Federation, Finland, Austria, Estonia, Hungary, Netherlands, Latvia, Italy, Mexico, Slovenia, Turkey, Bosnia and Herzegovina and more
Hoffmann-La Roche

Completed

A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer

Ovarian Cancer

France, Spain, Sweden, Hong Kong, Canada, Switzerland, Estonia, Greece, Russian Federation, Hungary, Austria, Bulgaria, Netherlands, Latvia, Italy, Slovenia, Turkey, Serbia, Israel, Argentina, Brazil, Slovakia, Lithuania, Poland, Portugal, Mexi... and more
Pharmacyclics LLC.

Completed

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Carcinoma, Non-Small-Cell Lung | Brain Neoplasms | Metastases, Neoplasm

United States, France, Belgium, Germany, Canada, Netherlands, Austria, Australia
Synta Pharmaceuticals Corp.

Terminated

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-Small-Cell Lung Adenocarcinoma

United States, France, Spain, Netherlands, Czech Republic, Serbia, Romania, Germany, Belgium, Italy, Hungary, United Kingdom, Canada, Poland, Bosnia and Herzegovina, Austria, Slovenia, Croatia, Russian Federation, Ukraine
Mirati Therapeutics Inc.
Bristol-Myers Squibb

Active, not recruiting

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (SAPPHIRE)

Metastatic Non-Squamous Non-Small Cell Lung Cancer

United States, Canada, Belgium, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, Switzerland, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)

Bladder Cancer

Canada, France, Italy, Netherlands, Turkey, Brazil, Spain, United States, Finland, Puerto Rico, Singapore
Pfizer

Active, not recruiting

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

Renal Cell Cancer

United States, Hungary, Spain, United Kingdom, Belgium, Korea, Republic of, Canada, Israel, Denmark, Australia, Italy, Japan, France, Austria, New Zealand, Romania, Russian Federation, Netherlands, Germany, Mexico, Sweden
Merck Sharp & Dohme LLC

Recruiting

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Uterine Cervical Neoplasms | Stomach Neoplasms | Urinary Bladder Neoplasms | Hepatocellular Carcinoma | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Neoplasms

United States, Chile, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, Turkey, Canada
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom, Mexico
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Spain, Belgium, France, Germany, Hungary, Italy, United Kingdom, Korea, Republic of, Poland, Australia, Switzerland, Singapore, Netherlands, Romania, Czechia, Greece, Ireland, Austria, Russian Federation, Portugal, Hong... and more
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Medullary Thyroid Cancer

United States, Canada, Spain, China, Australia, Japan, India, Germany, France, Netherlands, Czechia, Brazil, Korea, Republic of, Italy, Israel, Greece, United Kingdom, Belgium, Poland, Russian Federation
Genentech, Inc.
Hoffmann-La Roche

Completed

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Non-Squamous Non-Small Cell Lung Cancer

Poland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
Novartis Pharmaceuticals

Active, not recruiting

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Ovarian Cancer

United States, Italy, United Kingdom, Malaysia, Taiwan, Turkey, Belgium, Canada, Spain, Singapore, Austria, Denmark, Korea, Republic of, Australia, China, France, Netherlands, Russian Federation, Germany, Argentina, Mexico, Finland, Portuga... and more
Mirati Therapeutics Inc.

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer

Canada, United States, Korea, Republic of, Israel, Spain, United Kingdom, Belgium, Germany, Netherlands, Hungary, Italy, Czechia, Australia, Austria, Poland, Argentina, Brazil, Bulgaria, Chile, Colombia, France, Georgia, Greece, Ireland, Malays... and more
Amgen

Terminated

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Cancer | Anemia | Non-Small Cell Lung Cancer | Lung Cancer

United States, Belgium, Italy, Poland, Switzerland, Canada, Germany, Russian Federation, China, Taiwan, United Kingdom, Hong Kong, Austria, Brazil, Israel, South Africa, Czechia, Greece, Spain, Netherlands, Bulgaria, Romania, Ireland, Puerto Rico and more

Clinical Trials on Endometrioid Carcinoma in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations